Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder
Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R
The Journal of clinical psychiatry · 73 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- National Alliance for Research on Schizophrenia and Depression
Según 1 financiador declarado.
Publicación
- Publicado
- 2013-11-15 · J Clin Psychiatry · vol. 74 · número 11 · págs. 1076–1083
- Editorial
- Physicians Postgraduate Press, Inc.
- Citado
- 120 citas · más que el 90% de estudios similares · 3.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 50 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Bipolar Disorder and Treatment · Phytochemicals and Medicinal Plants · Schizophrenia research and treatment
- Palabras clave
- Withania somnifera, ashwagandha extract, bipolar disorder, cognitive impairment, working memory, backward digit span, reaction time, social cognition, adjunctive therapy, herbal medicine, maintenance therapy, flanker task, adverse events, treatment-resistant bipolar disorder
- MeSH
- humans, withania, antimanic agents, plant extracts, drugs, investigational, phytotherapy, drug therapy, combination, double-blind method, memory, short-term, attention, reaction time, cognition disorders, bipolar disorder, neuropsychological tests, psychometrics, adult, middle aged, female, male, executive function
6 autores
- K. N. Roy Chengappa🇺🇸 · autor de correspondenciaUniversity of Pittsburgh Medical Center
- Christopher R. Bowie🇺🇸University of Pittsburgh Medical Center
- Patricia J. Schlicht🇺🇸University of Pittsburgh Medical Center
- David Fleet🇺🇸University of Pittsburgh Medical Center
- Jaspreet Singh Brar🇺🇸University of Pittsburgh Medical Center
- Ripu Daman Jindal🇺🇸University of Pittsburgh Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Cognitive impairments contribute significantly to inadequate functional recovery following illness episodes in bipolar disorder, yet data on treatment interventions are sparse. We assessed the cognitive effects of a standardized extract of the medicinal herb Withania somnifera (WSE) in bipolar disorder.
Method
Sixty euthymic subjects with DSM-IV bipolar disorder were enrolled in an 8-week, double-blind, placebo-controlled, randomized study of WSE (500 mg/d) as a procognitive agent added adjunctively to the medications being used as maintenance treatment for bipolar disorder. Study enrollment and data analyses were completed between December 2008 and September 2012. Cognitive testing at baseline and 8 weeks assessed primary efficacy outcomes. Psychopathology and adverse events were monitored at scheduled visits.
Results
Fifty-three patients completed the study (WSE, n = 24; placebo, n = 29), and the 2 groups were matched in terms of demographic, illness, and treatment characteristics. Compared to placebo, WSE provided significant benefits for 3 cognitive tasks: digit span backward (P = .035), Flanker neutral response time (P = .033), and the social cognition response rating of the Penn Emotional Acuity Test (P = .045). The size of the WSE treatment effect for digit span backward was in the medium range (Cohen d = 0.51; 95% CI, 0.25-0.77). None of the other cognitive tasks showed significant between-group differences. Mood and anxiety scale scores remained stable, and adverse events were minor.
Conclusions
Although results are preliminary, WSE appears to improve auditory-verbal working memory (digit span backward), a measure of reaction time, and a measure of social cognition in bipolar disorder. Given the paucity of data for improving cognitive capacity in bipolar disorder, WSE offers promise, appears to have a benign side-effects profile, and merits further study.
Trial registration
ClinicalTrials.gov identifier: NCT00761761.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.